On March 3, 2021, The National Comprehensive Cancer Network (NCCN) released an update to its guideline for non-small cell lung cancer (NSCLC).
In the section for first-line therapy for PD-L1 expression-positive NSCLC ≥50% and negative for actionable molecular markers, cemiplimab-rwlc was added as a preferred, category 1, treatment option.
Additionally, in the section for targeted therapy or immunotherapy for advanced or metastatic disease, cemiplimab-rwlc was added as first-line therapy for PDL1 ≥50% NSCLC.—Janelle Bradley
